Drug intelligence / Profile preview

KA-301

Development stage: Unknown
Lead developer: Kaneka
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

KA-301 is an allogeneic cell therapy composed of human amnion-derived mesenchymal stem cells (AMSCs), developed by Kaneka Corporation. It is currently being investigated for the treatment of Duchenne muscular dystrophy (DMD). AMSCs are isolated from the amniotic membrane of the human placenta and are believed to function by secreting various trophic factors and cytokines that reduce muscle inflammation, inhibit fibrosis, and support the regeneration of damaged muscle tissue. In clinical trials, KA-301 is administered via intravenous infusion to ambulatory patients with DMD who are on stable corticosteroid therapy to evaluate its safety and exploratory efficacy.

Other names: amnion-derived mesenchymal stem cellshuman allogeneic amnion-derived mesenchymal stem cells

Beyond the preview

Go deeper on KA-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KA-301.

Explore the full profile